State of New Jersey Common Pension Fund D Has $1.94 Million Holdings in Azenta, Inc. (NASDAQ:AZTA)

State of New Jersey Common Pension Fund D increased its position in shares of Azenta, Inc. (NASDAQ:AZTA) by 9.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,008 shares of the company’s stock after acquiring an additional 3,469 shares during the quarter. State of New Jersey Common Pension Fund D owned 0.08% of Azenta worth $1,938,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Redwood Investment Management LLC acquired a new stake in shares of Azenta during the first quarter valued at approximately $1,497,000. Ontario Teachers Pension Plan Board acquired a new position in Azenta in the 1st quarter valued at approximately $1,401,000. Wesbanco Bank Inc. increased its stake in Azenta by 72.2% in the 3rd quarter. Wesbanco Bank Inc. now owns 31,000 shares of the company’s stock valued at $1,502,000 after buying an additional 13,000 shares during the period. American Century Companies Inc. increased its stake in Azenta by 66.3% in the 2nd quarter. American Century Companies Inc. now owns 69,955 shares of the company’s stock valued at $3,681,000 after buying an additional 27,882 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in Azenta in the 2nd quarter valued at approximately $222,000. Institutional investors and hedge funds own 99.08% of the company’s stock.

Azenta Stock Down 2.6 %

Shares of AZTA opened at $41.51 on Monday. The company’s fifty day moving average is $45.56 and its 200-day moving average is $50.43. Azenta, Inc. has a 12 month low of $40.24 and a 12 month high of $69.16. The firm has a market cap of $2.03 billion, a price-to-earnings ratio of -13.98 and a beta of 1.48.

Azenta (NASDAQ:AZTA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.10 by $0.08. The company had revenue of $170.00 million for the quarter, compared to analyst estimates of $169.66 million. Azenta had a negative net margin of 25.01% and a positive return on equity of 1.03%. Azenta’s quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.13 EPS. As a group, research analysts predict that Azenta, Inc. will post 0.4 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Herman Cueto sold 1,595 shares of the company’s stock in a transaction on Thursday, October 17th. The shares were sold at an average price of $43.68, for a total transaction of $69,669.60. Following the completion of the sale, the chief financial officer now directly owns 24,604 shares of the company’s stock, valued at approximately $1,074,702.72. This represents a 6.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.77% of the stock is owned by insiders.

Wall Street Analyst Weigh In

AZTA has been the topic of several research reports. Evercore ISI dropped their price objective on shares of Azenta from $53.00 to $50.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Needham & Company LLC dropped their price objective on shares of Azenta from $69.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, November 13th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $63.60.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.